Tirzepatide's dual receptor mechanism How tirzepatide works: Dual GIP/GLP-1 receptor agonist Single molecule, two pathways GIP (glucose-dependent insulinotropic polypeptide) + GLP-1 Weekly subcutaneous injection FDA approved for diabetes and obesity GIP pathway effects: Enhances insulin secretion Improves insulin sensitivity Promotes fat metabolism Reduces inflammation Works synergistically with GLP-1 GLP-1 pathway effects: Suppresses appetite (central brain effects) Slows gastric emptying (moderate) Increases satiety Reduces glucagon Improves glucose control Combined tirzepatide results: 15-22% average body weight loss (monotherapy) Superior to semaglutide (GLP-1 alone) Well-tolerated in trials Approved and available See our tirzepatide dosing guide , semaglutide vs tirzepatide , and peptides for weight loss at SeekPeptides
Dosage, Concentration, Route of Administration Dosage : Seek advice from an appropriately qualified and licensed physician, medical director, or other healthcare provider Concentration : 2mg/ml Route of Administration : IV/IM/SQ Resources: Precautions/Side Effects Hydroxocobalamin injections are contraindicated in people with low blood potassium or allergies to vitamin B12 or cobalt
Philp, D., Badamchian, M., Scheremeta, B., Nguyen, M., Goldstein, A
If your test comes with a color chart, consult this to determine the level of contamination
Gut surgery, pancreatic insufficiency, small intestinal bacterial overgrowth (SIBO), parasite infections, and certain autoimmune disorders are considered additional risk factors
It has been reported that HT patients exhibit abnormal DNA methylation patterns, which are important epigenetic changes that contribute to gene silencing and lead to changes in gene expression (Pu And Zhang 2024)
